IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Ranbaxy’s Controversial India Plant Gets Australian, U.K. Regulatory Approvals

2:13 AM MDT | March 23, 2009 | Deepti Ramesh

Ranbaxy Laboratories (Gurgaon, India) says that the Medicines and Healthcare products Regulatory Agency (MHRA; London) of the U.K., and the Therapeutic Goods Administration (TGA; Canberra), Australia’s drug regulatory body, have issued good manufacturing practice (GMP) certificates for Ranbaxy’s Paonta Sahib, India manufacturing facility, following a joint audit conducted last October. Ranbaxy says that the MHRA approval will cover product filings for the U.K. and also apply to product filings for the entire European Union. The U.S. FDA said last...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa